Key Highlights
- Shareholders approved a £2.85-per-share cash offer from H.B. Fuller with about 84% support
- Deal values AMS at an Enterprise value of around £715m
- Structured as a court-sanctioned scheme of arrangement
- H.B. Fuller framed the price at 12.9x pre-synergy 2026 EBITDA, falling below 8x with synergies
- Completion and AIM delisting expected by the end of 2026
- Deal backed by fully committed financing, with H.B. Fuller targeting deleveraging to 2.5x-3x within two years
After years as one of AIM's steadier medical-technology performers, Advanced Medical Solutions Group (LSE:AMS) is heading towards the exit. On 12 August 2026 its shareholders voted decisively in favour of a recommended cash Acquisition by H.B. Fuller, the US-listed industrial and speciality adhesives group, clearing a key hurdle towards a Takeover that will remove the Winsford-based company from public markets. The vote marks the near-conclusion of a courtship that began with H.B. Fuller's approach in June.
What Has Happened?
H.B. Fuller announced its recommended cash offer for AMS on 24 June 2026, proposing £2.85 per share and implying a total enterprise value of about £715m. The deal is being effected as a court-sanctioned scheme of arrangement, transferring all AMS shares to a H.B. Fuller subsidiary. At the Shareholder meetings held on 12 August 2026, both the court meeting and the general meeting passed the required resolutions with approximately 84% support, comfortably clearing the thresholds needed to proceed.
With shareholder approval secured, the transaction now depends on remaining regulatory and court steps. Management and the acquirer expect completion, and the associated cancellation of AMS's AIM listing, by the end of the 2026 calendar year.
The Numbers Investors Need to Know
The core terms are straightforward: £2.85 in cash per AMS share, valuing the Business at an enterprise value of roughly £715m (broadly equivalent to around $940m at prevailing exchange rates). H.B. Fuller framed the price as 12.9x AMS's consensus pre-synergy 2026 EBITDA, falling to under 8x once full run-rate synergies are included.
The vote outcome — approximately 84% in favour at both the court meeting and the general meeting on 12 August — provides the shareholder mandate. H.B. Fuller has said the acquisition is backed by fully committed financing and expects to deleverage to 2.5x-3x within roughly two years of completion, indicating confidence in the combined group's cash generation. AMS's Market Capitalisation had been quoted at around £608m ahead of the vote, reflecting the Market Value implied by the offer.
Why This Matters
For AMS shareholders, the deal crystallises a cash exit at a premium multiple, ending the company's near-three-decade run as an independent listed business. Advanced Medical Solutions built a respected niche in surgical tissue adhesives, sealants and advanced wound-care products, and its technology is a natural strategic fit for H.B. Fuller, whose adhesives expertise extends across industrial and, increasingly, medical applications. H.B. Fuller's chief executive called AMS "an exceptional company and a rare strategic fit that advances our vision for the future".
More broadly, the transaction is another example of overseas acquirers taking UK-listed, technology-rich small and mid-caps private — a recurring theme that speaks to persistent valuation gaps between London-listed Assets and international strategic buyers. AMS has spent much of its life on AIM, London's junior market, where smaller companies frequently trade at a discount to the multiples strategic acquirers are prepared to pay. The 12.9x pre-synergy EBITDA multiple H.B. Fuller has offered sits well above where many UK small-caps have been rated in recent years, which helps explain why the board recommended the deal and why shareholders backed it so heavily. Each such departure thins the pool of quality mid-cap healthcare names available to UK investors.
What Is Driving the Story?
The deal logic is rooted in complementary technology. H.B. Fuller gains a specialist medical-adhesives and wound-care platform, adding higher-margin healthcare exposure to its adhesives portfolio and, on its own analysis, meaningful synergies that lower the effective purchase multiple to below 8x EBITDA. For AMS's board, a recommended all-cash offer at 12.9x forward EBITDA offered shareholders certain value at a full multiple, prompting its recommendation to accept.
The near-unanimous 84% vote in favour reflects that recommendation and the appeal of a clean cash exit, particularly for a company whose AIM listing may have constrained its rating relative to larger, better-capitalised strategic owners. For H.B. Fuller, the structure is telling: with fully committed financing in place and a plan to deleverage to 2.5x-3x within roughly two years, the US group is treating AMS as a strategic bolt-on expanding its medical-adhesives footprint, not a financially engineered deal. The scheme-of-arrangement route, requiring both a court meeting and a general meeting, is the standard UK mechanism for a friendly takeover, and the comfortable margins by which both resolutions passed leave little doubt about shareholder intent.
What Could Drive the Shares Next?
With the offer fixed at £2.85 in cash, the share price is now anchored close to that level, and the principal remaining variables are procedural. The key milestones are final court sanction of the scheme and satisfaction of any outstanding regulatory conditions; reporting to date has indicated no substantive competition concerns. Assuming those steps complete as expected by year-end, the shares will be cancelled from AIM and holders will receive their cash consideration. The main risk to the price is a failure or delay of the scheme, which would reintroduce uncertainty; absent that, there is limited scope for further upside beyond the agreed terms.
Risks Investors Should Watch
Even a well-supported scheme is not risk-free until sanctioned. Regulatory approvals — including any competition clearances in the relevant jurisdictions — remain a condition, and unexpected intervention could delay or, in the extreme, derail completion. Court sanction of the scheme is a formal but necessary final step. For holders weighing whether to sell in the market versus await consideration, the small spread to the Offer Price reflects residual completion risk and timing. Should the deal lapse, AMS shares would likely reprice back towards pre-offer levels, removing the takeover premium. There is also limited optionality of a competing bid at this late stage, given the board recommendation and the strong shareholder vote already secured.
The Bottom Line
The 12 August vote effectively seals the fate of Advanced Medical Solutions (LSE:AMS) as an independent company. A recommended £2.85-per-share cash offer from H.B. Fuller, valuing the group at an enterprise value of around £715m and endorsed by roughly 84% of voting shareholders, is now on track to complete and delist the business by the end of 2026. For shareholders, the deal delivers a clean cash exit at a full forward multiple; for H.B. Fuller, it adds a respected medical-adhesives and wound-care Franchise with attractive synergies. Barring a regulatory or procedural upset, the remaining steps are largely mechanical — and AMS's long chapter on public markets is drawing to a close.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...